To observe the risk of thrombosis in hematologic malignancies, we examined the levels of inflammatory factors IL-1β, TNF-α, TGF-β, and MCP-1 as well as coagulation factors FVIII, TF, P-selectin, thrombin, and fibrinogen in the plasma of patients with lymphoma. This evidence concerns the gene CCL2 and hematologic disorder.